Acrux Ltd (ASX: ACR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Acrux Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Acrux Ltd (ASX: ACR)
Latest News
⏸️ Investing
Why these 4 ASX shares are getting hammered today
⏸️ Investing
6 listed funds with tax free capital gains and dividends
⏸️ Investing
Are Acrux Limited shares a buy?
⏸️ Investing
Why the Acrux Limited share price was hammered in July
⏸️ Investing
Morning market movers: 17 stocks to watch
⏸️ Investing
Why these 4 ASX stocks are falling today
⏸️ Investing
3 stocks at 52-week lows – can they turn it around?
⏸️ Investing
Why these 5 stocks are crumbling today
⏸️ Investing
Acrux Limited sales crash: What you need to know
⏸️ Investing
Morning market movers: 10 stocks to watch
⏸️ Investing
Strategic Elements Ltd surges 600%: What you need to know
⏸️ Investing
Acrux Limited posts quarterly results: Is it a buy?
ACR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Acrux Ltd
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and othercountries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone TopicalSolution, and among others.
ACR Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
06 Sep 2024 | $0.06 | $0.00 | 0.00% | 321,844 | $0.06 | $0.06 | $0.06 |
05 Sep 2024 | $0.06 | $0.00 | 0.00% | 242,413 | $0.06 | $0.06 | $0.06 |
03 Sep 2024 | $0.06 | $0.00 | 0.00% | 536,344 | $0.06 | $0.06 | $0.06 |
02 Sep 2024 | $0.06 | $0.00 | 0.00% | 242,395 | $0.06 | $0.06 | $0.06 |
30 Aug 2024 | $0.07 | $0.00 | 0.00% | 317,935 | $0.06 | $0.07 | $0.06 |
29 Aug 2024 | $0.06 | $0.00 | 0.00% | 584,947 | $0.06 | $0.07 | $0.06 |
28 Aug 2024 | $0.06 | $-0.01 | -15.15% | 945,342 | $0.07 | $0.07 | $0.06 |
27 Aug 2024 | $0.07 | $0.01 | 16.67% | 5,742,778 | $0.07 | $0.08 | $0.07 |
26 Aug 2024 | $0.06 | $0.00 | 0.00% | 268,262 | $0.06 | $0.06 | $0.06 |
23 Aug 2024 | $0.06 | $0.00 | 0.00% | 225,029 | $0.06 | $0.06 | $0.06 |
22 Aug 2024 | $0.06 | $0.00 | 0.00% | 49,691 | $0.06 | $0.06 | $0.06 |
21 Aug 2024 | $0.06 | $0.00 | 0.00% | 334,233 | $0.06 | $0.06 | $0.06 |
20 Aug 2024 | $0.06 | $0.00 | 0.00% | 306,865 | $0.06 | $0.06 | $0.06 |
19 Aug 2024 | $0.06 | $0.00 | 0.00% | 4,393 | $0.06 | $0.06 | $0.06 |
16 Aug 2024 | $0.06 | $0.00 | 0.00% | 154,308 | $0.06 | $0.06 | $0.06 |
15 Aug 2024 | $0.06 | $0.00 | 0.00% | 164,486 | $0.06 | $0.06 | $0.06 |
14 Aug 2024 | $0.06 | $0.00 | 0.00% | 733,840 | $0.06 | $0.07 | $0.06 |
13 Aug 2024 | $0.07 | $0.00 | 0.00% | 40,045 | $0.06 | $0.07 | $0.06 |
12 Aug 2024 | $0.06 | $0.00 | 0.00% | 69,828 | $0.06 | $0.06 | $0.06 |
09 Aug 2024 | $0.06 | $0.00 | 0.00% | 54,398 | $0.07 | $0.07 | $0.06 |
08 Aug 2024 | $0.07 | $0.01 | 16.67% | 501,385 | $0.06 | $0.07 | $0.06 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
05 Mar 2024 | Ross Dobinson | Exercise | 418,851 | $23,036 |
Conversion of securities.
|
05 Mar 2024 | Ross Dobinson | Buy | 418,851 | $23,036 |
Conversion of securities.
|
05 Mar 2024 | Donald Brumley | Exercise | 265,736 | $14,615 |
Conversion of securities. 797,210 Unlisted Rights
|
20 Dec 2023 | Geoffrey Brooke | Buy | 138,187 | $6,218 |
Conversion of securities.
|
20 Dec 2023 | Geoffrey Brooke | Exercise | 138,187 | $6,218 |
Conversion of securities. 1,062,946 rights
|
20 Dec 2023 | Timothy Oldham | Buy | 414,561 | $18,655 |
Conversion of securities.
|
20 Dec 2023 | Timothy Oldham | Exercise | 414,561 | $18,655 |
Conversion of securities. 1,062,946 unlisted rights
|
05 Dec 2023 | Geoffrey Brooke | Issued | 1,062,946 | $52,084 |
Issue of securities. 12,01,133 Rights
|
05 Dec 2023 | Timothy Oldham | Issued | 1,062,946 | $52,084 |
Issue of securities. 14,77,507 Rights
|
05 Dec 2023 | Ross Dobinson | Issued | 1,675,405 | $82,094 |
Issue of securities. 1,675,405 unlisted rights
|
05 Dec 2023 | Donald Brumley | Issued | 1,062,946 | $52,084 |
Issue of securities. 1,062,946 Unlisted Rights
|
24 Nov 2023 | Ross Dobinson | Buy | 237,610 | $10,217 |
Conversion of securities.
|
24 Nov 2023 | Ross Dobinson | Exercise | 237,610 | $10,217 |
Conversion of securities.
|
24 Nov 2023 | Donald Brumley | Exercise | 138,187 | $5,942 |
Conversion of securities.
|
24 Nov 2023 | Donald Brumley | Buy | 138,187 | $5,942 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Ross Dobinson | Non-Executive ChairmanNon-Executive Director | Jul 2012 |
Mr Dobinson has been a Director since 1998, was appointed Chairman in January 2006 and then Executive Chairman from July 2012 to October 2014. He is a founder and former CEO of Acrux. Mr Dobinson has a background in investment banking and stockbroking.
|
Dr Geoffrey E.D Brooke | Non-Executive Director | Jun 2016 |
Mr Brooke joined the Board in June 2016. He founded GBS Venture Partners Pty Ltd in 1996 and has more than 20 years of venture capital experience. In January 2014, he reduced his involvement in GBS and is now special adviser to the firm and its funds. Mr Brooke was formally President of Medvest Inc., a US-based early-stage venture capital group he founded with Johnson & Johnson. Mr Brooke's experience includes company formation and acquisitions, as well as public listings on the NYSE, NASDAQ and ASX exchanges. Mr Brooke is licensed in clinical medicine by the Medical Board of Victoria, Australia and his postgraduate work was in anaesthetics and intensive care.
|
Dr Timothy Oldham | Non-Executive Director | Oct 2013 |
Mr Oldham has 20 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. Mr Oldham is the CEO and Managing Director at AdAlta Ltd (ASX: 1AD). AdAlta is a clinical stage biotech company developing an innovative range of new antibody-like drugs. Prior to this, he was Executive Leader of Tijan Ventures, an advisory business focussed on growing life sciences companies through strategic advisory and interim leadership services and acquiring cell and gene therapy assets. He was previously CEO and Managing Director of Cell Therapies Pty Ltd and President of Asia Pacific for Hospira, Inc., having held a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. These roles encompassed the development and commercialisation of generic pharmaceuticals, devices, biologics and cellular therapies. Mr Oldham began his business career as an engagement manager with McKinsey & Company.
|
Mr Michael John Kotsanis | Chief Executive OfficerManaging Director | Nov 2014 |
Mr Kotsanis is a seasoned executive with over 30 years of experience in the pharmaceutical industry and has significant senior leadership experience across the global pharmaceutical markets. He was formerly the Chief Commercial Officer and a Board Member of Synthon Holding BV, a Dutch based pharmaceutical company with global revenue over EUR250 million. Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira and where he was responsible for delivering over US$500 million in annual revenue. Hospira was the global leader in generic injectable pharmaceuticals prior to its acquisition by Pfizer. Mr Kotsanis joined Hospira following its acquisition of Mayne Pharma in 2007, where he had served as President, Asia Pacific. He joined Mayne following their acquisition of FH Faulding in 2001, where he held responsibility for commercial activities of the pharmaceutical business in Australia and New Zealand. Prior to Faulding, Mr Kotsanis held a variety of sales and marketing positions with a German multinational pharmaceutical company over an 11 year period.
|
Mr Donald Charles Brumley | Non-Executive Director | Jun 2021 |
Mr Brumley has 30 years' experience as a senior partner of Ernst & Young, Oceania. He has eexperience in IPOs, transactions and audit and has advised and worked with Boards of organisations ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations. Mr Brumley was the Oceania IPO Leader at Ernst & Young and worked with clients listing on the Australian, US, UK and key Asian stock exchanges. He held positions as Biotech Markets Leader, National Leader of Strategic Growth Markets and on the Board of Partners of Ernst & Young. He is a Fellow of Chartered Accountants Australia & New Zealand and is a member of the Australian Institute of Company Directors.
|
Ms Joanna Johnson | Chief Financial OfficerCompany Secretary | Jun 2021 |
-
|
Joanna Johnson | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Phillip Asset Management Limited | 31,847,134 | 11.05% |
Citicorp Nominees Pty Limited | 4,831,059 | 1.68% |
Hishenk Pty Ltd | 4,500,000 | 1.56% |
Dr Thomas Vui Chung Chai | 4,460,560 | 1.55% |
Mr Ross Dobinson | 4,355,174 | 1.51% |
Pacific Custodians Pty Limited | 3,849,912 | 1.34% |
Ashwood River Pty Ltd | 3,800,000 | 1.32% |
Ddh Graham Limited | 3,682,818 | 1.28% |
Mr Paul Cozzi | 3,259,121 | 1.13% |
Mr Christopher Murray Abbott | 3,000,000 | 1.04% |
The Poole Family Superannuation Fund Pty Ltd | 3,000,000 | 1.04% |
Mr Donald Charles Brumley | 2,853,998 | 0.99% |
Tso Pty Ltd | 2,625,734 | 0.91% |
Mr Alan Jebb & Mrs Sandra Jebb | 2,430,707 | 0.84% |
Willoughby Capital Pty Ltd | 2,300,000 | 0.80% |
Mr Ian Victor Lancini & Mrs Debra Ann Lancini | 2,045,000 | 0.71% |
Mr Bikash Kaji Baniya | 2,012,119 | 0.70% |
Adam Jamal | 1,905,719 | 0.66% |
Durbin Superannuation Pty Ltd | 1,727,640 | 0.60% |
Asia Union Investments Pty Limited | 1,691,083 | 0.59% |
Hsbc Custody Nominees (Australia) Limited | 1,657,801 | 0.58% |
Neweconomy Com Au Nominees Pty Limited | 1,511,799 | 0.52% |
Mr Michael John Kotsanis | 1,511,083 | 0.52% |
Mr David Andrew Slobom & Mrs Linda Jane Slobom | 1,409,596 | 0.49% |
Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken | 1,319,986 | 0.46% |
Morgan Stanley Australia Securities (Nominee) Pty Limited | 1,306,852 | 0.45% |